Efficacy and safety of the PCSK9 inhibitor alirocumab 300 mg every 4 weeks in patients with ASCVD.Eli Roth,Patrick M Moriarty,Jean Bergeron,Gisle Langslet,Garen Manvelian,Jian Zhao,Marie T Baccara-Dinet,Daniel J RaderATHEROSCLEROSIS(2017)引用 1|浏览10暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要